CUE is trading at approximately $29.68 (6% down) as the stock experiences profit-taking and volatility typical of small-cap biotech following a series of major catalysts.
- The recent rally was driven by a $30 million financing round and a $7.5 million milestone payment from partner Boehringer Ingelheim.
- Investor sentiment was further bolstered by the strategic in-licensing of Ascendant-221 (CUE-221) to expand the company's pipeline.
- Today's decline follows a significant multi-day surge, reflecting a period of consolidation after the recent positive news flow.